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Background: Cholestasis is characterized by an abnormal accumulation of bile acids and causes hepatocellular
injury. Recent studies show that autophagy is involved in the pathophysiology of many liver diseases. The potential
role of autophagy in preventing cholestatic hepatotoxicity, however, has rarely been investigated. The aim of this
study was to examine whether autophagy is involved in the cholestatic hepatotoxicity.
Results: We found that bile duct ligation (BDL) led to cholestatic liver injury and hepatocytic autophagy activation
in the mice. Suppression of autophagy with Chloroquine (CQ) increased liver injury and hepatocytes apoptosis;
while activation of autophagy by rapamycin reduced cholestasis hepatotoxicity. In L02 normal liver cells,
Glycochenodeoxycholate (GCDC) treatment would induce autophagy. Inhibition of autophagy by CQ could
promote GCDC-induced cell apoptosis. In contrast, rapamycin treatment could protect against GCDC-induced cell
death. Furthermore, autophagy contributed to the liver cells survival via modulation of reactive oxygen species
(ROS).
Conclusions: These findings indicate that autophagy protects against cholestasis induced liver injury and
hepatocyte apoptosis by eliminating ROS accumulation. Our data suggest that enhancement of autophagy may be
a therapeutic strategy to mitigate cholestatic liver injury.
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Cholestasis is a commonly clinical pathology of many
diseases, which is characterized by an abnormal accumu-
lation of bile acids. Many liver diseases have been dem-
onstrated to have cholestatic pathophysiology, such as
cholangiocarcinoma, bile duct stone, primary biliary cir-
rhosis, biliary atresia, and primary sclerosing cholangitis
[1-3]. Initial studies suggested that the accumulation of
hydrophobic bile acids in the liver contributes to chole-
stasis associated liver injury [4], and that Glycocheno-
deoxycholate (GCDC), the main toxic component of bile
acid in patients, could induce necrosis in freshly isolated
hepatocytes and primary cultured hepatocytes [5,6], or* Correspondence: weilixin_smmu@163.com
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unless otherwise stated.induce apoptosis in isolated liver cell models [7,8]. In re-
cent years, the possible molecular mechanisms of liver
damage induced by cholestasis, including oxidative
stress, mitochondrial damage, and cell membrane dis-
ruption through their detergent action on lipid compo-
nents have been found in bile acid-induced hepatocyte
death. Despite this observation, the definitive mecha-
nisms that underlie the hepatic injury during cholestatic
liver diseases remain incompletely understood.
Autophagy is a catabolic process that enables cells to
recycle amino acids and other intracellular nutrients to
obtain energy [9]. It is believed to be a mechanism for
selective elimination of protein and dysfunctional organ-
elles that are damaged under pathological conditions
[10]. Autophagy dysfunction is associated with various
diseases, such as cancer, neurodegeneration, gastrointes-
tinal disorders, microbial infection, and aging [11]. The
genes that regulate autophagy were first identified in
yeasts. Among them, LC3, a marker of autophagosomes
in mammalian cells, is activated and then relocalizes to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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questers cytoplasm to form autophagosmes [12]. In
addition, p62 is a multifunctional protein that binds to
LC3 and to ubiquitinated proteins, which mediates the
recognition of protein aggregates for autophagic clearance
[13]. The accumulation of p62 marks the dysfunctional
autophagy which is not enough to process the damaged
proteins bound to p62 [14]. In recent years, various stud-
ies reported that autophagy actively participates in liver
physiology and pathogenesis [15,16]. In liver, it was found
that autophagy plays important roles in cytoprotection
against multiple pathological insults, including liver stea-
tosis, liver injury, dyslipidemia in alcoholic, and non-
alcoholic fatty liver conditions [17-20]. However, whether
autophagy plays roles in cholestasis is unclear.
In this study, we investigated whether the autophagy
machinery could be activated in liver injury induced by
cholestasis; we hypothesized that autophagy contributes
to the cell survival via reactive oxygen species (ROS)
modulation in hepatocytes.
Results
Bile duct ligation promoted autophagy in the mouse liver
In this part, we carried out a bile duct ligation (BDL)
experiment to mimic the pathophysiogical process of cho-
lestasis in vivo. Mice were euthanized after 2 weeks post-
BDL or sham surgery. Blood was collected and ALT and
AST activities were quantified. As shown in Figure 1A,
Both ALT, AST and TBIL levels were significantly elevated
in BDL group, indicating that BDL led to hepatic injury
and cholestasis accumulation in mice liver. In the subse-
quent research, we observed the changes in autophagy
after treatment with BDL. Since autophagy is generally
considered as a protective mechanism in response to
stresses, such as starvation, hypoxia and DNA damage, we
detected the impact of BDL on autophagy level of liver
cells in mice. LC3 is a special marker for indicative of
autophagosomal activation. Detection of the conversion
from LC3-I (cytosolic form) to LC3-II (membrane-bound
lipidated form) by immunoblotting is considered as a hall
mark of autophagic activity [21]. Through the blot of LC3,
the expression of LC3-II level was markedly increased in
BDL group, whereas that of the control group was weak
(Figure 1B). Furthermore, electron microscope also
showed an apparent double-membrane vacuolar struc-
tures with feature of autophagosome following treatment
of BDL, but the number of autophagosome was rarely de-
tected in the livers of the control group (Figure 1C and
D). These results suggest that bile duct ligation leads to
liver injury and activation of autophagy.
GCDC induced autophagy in L02 hepatocytes
Since GCDC is the main toxic component of bile acid in
cholestasis-induced injury, we treated L02 normal livercells with GCDC to mimic cholestatic damage in our
current study. The L02 cells were transfected with GFP-
LC3 plasmid and analyzed by microscopy. Our results
showed that GCDC treatment increased GFP-LC3 dots in
the L02 liver cells in a time-dependent manner (Figure 2A
and B). Electron microscopic analysis was then employed
to observe the autopahgosomes. The results suggested the
presence of characteristic double-membrane organelles in
L02 cells pretreated with GCDC (Figure 2C and D). In
addition, immunoblot analysis of endogenous LC3 (LC3-I
to LC3-II) was markedly increased in a time- and dose-
dependent manner upon GCDC stimulation, indicating a
significantly increased formation and degradation in the
group. Moreover, the amount of p62, a selective substrate
of autophagy and an autophagy-related marker, was also
markedly degraded given the GCDC in a time and dose
study (Figure 2E and F). Taken together, these observa-
tions imply that GCDC acids could activate autophagy in
hepatocytes in vitro.
Autophagy protects against BDL-induced liver injury
Among the potential protective mechanisms, we hypothe-
sized that activation of autophagy could play a role in
limiting cholestasis-induced hepatotoxicity. Autophagic
inhibitor-chloroquine (CQ) and inducer-rapamycin were
applied. In our study, C57BL/6 mice were pretreated with
rapamycin or CQ intraperitoneally two weeks earlier be-
fore BDL induction. As shown in Figure 3A, pretreatment
of mice with CQ significantly elevated liver enzymes as
measured by blood ALT and AST level, indicating that
CQ addition greatly exacerbated BDL-induced liver injury.
Meanwhile, treatment with rapamycin partly eliminated
BDL-induced liver damage. CQ or rapamycin alone
showed a slight shrinkage, suggesting that they had no sig-
nificant effect on liver function. It is reported that chole-
stasis induced liver injury by increasing hepatocyte
apoptosis, thus we examined the impact of autophagy on
the survival of liver cell under BDL by TUNEL staining
and H&E, respectively. As shown in Figure 3B, the mice
of CQ+ BDL group had higher percentage of the apop-
totic cells (Tunnel-positive) compared to those of BDL
group. However, co-treatment of rapamycin and BDL de-
creased the number of apoptotic hepatocytes (Figure 3B
and C). Meanwhile, H&E staining were also performed to
determine the liver damage. Both treatments of BDL and
CQ+ BDL had significant liver injury as focal necrosis was
evident in livers; Necrosis increased following CQ+ BDL
while rapamycin treatment effectively reversed this rate.
(Figure 3D). These results showed that autophagy inducer
could partly resist cholestatic injury but inhibitor of au-
tophagy aggravates it, which is consistent with our hy-
pothesis that autophagy may be an important protector to
cholestasis-induced liver injury. Taken together, these
findings indicated that autophagy plays an active role in
Figure 1 Bile duct ligation leads to liver injury and activation of autophagy. (A) Plasma ALT, AST and TBIL levels were analyzed in mice
treated with either BDL or control after 2 weeks. Data were expressed as mean ± SD. (*: P < 0.05). (B) Representative liver sections were collected
from the mice of BDL and control group, then protein levels of LC3 of liver samples were analyzed by an immunoblot assay. (C) The liver
samples were processed for electron microscope and representative electron micrographs were shown. Arrows denote autophagosomes.
(N: nucleus; Bar: 20 μm). (D) Data were derived from three independent experiments. (*: P < 0.05).
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apoptosis or necrosis.
Activation of autophagy reduced GCDC-induced hepatocyte
apoptosis
To further determine the role of autophagy on liver in-
jury, in vitro studies were established. The autophagy in-
hibitor CQ and inducer rapamycin were used to
examine the effects of autophagy in the injury of L02
cells by GCDC treatment. We found that pretreatment
of L02 cells with CQ further increased the levels of
GFP-LC3 puncta and LC3 form (Figure 4A,B and C),
and treatment of hepatocytes with rapamycin confirmed
the induction of autophagy induced by GCDC. It is with
no doubt that autophagy was activated in response to
GCDC. To investigate the effect of GCDC on cell death,
the apoptosis of liver cells was examined by Annexin
V-FITC assay. Futher, the PI staining rate (considered as
reflecting necrotic cells) and the Annexin-V binding rate
(reflecting apoptotic cells) were quantified, respectively.
Figure 4D showed that both treatments of GCDC and
CQ +GCDC caused obvious elevated necrosis in L02
cells; however, there was no significant difference be-
tween them (data not shown). On the contrary, the per-
centage of apoptotic cells in the group of CQ +GCDC
was significantly higher than that of GCDC alone. There
were only 22.2% and 42.9% apoptotic cells in GCDCgroup and CQ +GCDC group, respectively. Meanwhile,
the percentage of apoptosis was 21.1% in the DMSO +
GCDC group, while it reduced to 10.1% in the Rap +
GCDC group (Figure 4E). Compared with GCDC alone,
necrosis in CQ and GCDC combined treatment group
showed no significant difference but apoptosis was much
higher, suggesting that GCDC induced apoptosis, but
not necrosis caused by hepatic injury of GCDC. Thus,
our data imply that induction of autophagy protects
against GCDC-induced apoptosis, but not necrosis.
These results further confirm that autophagy prevents
hepatocytes damage, and that rapamycin preserves liver
death, at least partly, by enhancing autophagy.
ROS contributes to cholestasis-induced liver injury
GCDC has been known as an inducer of oxidative stress,
and increased ROS lead to hepatocyte damage [22,23].
To determine whether ROS is involved in GCDC in-
duced by cholestasis, we examined the role of DCF, a
measure of hydroperoxide generation for ROS. As
shown in Figure 5A, intracellular levels of ROS were de-
tected. ROS expression was increased when treated with
GCDC, while there were marked increased in cells with
CQ combination. At the same time, we also explored
whether the generation of ROS was an important event
in vivo. 8-Hydroxy-2’deoxy Guanosine (8-OHdG), an in-
dicator of DNA oxidative damage, in liver tissue of mice
Figure 2 Glycochenodeoxycholic acid induces autophagy in L02 hepatocytes. (A and B) The L02 normal hepatocytes cells were transfected
with GFP-tagged LC3 and then pretreated with GCDC (200 μM) as indicated (for 2, 12, and 24 hours). Images were taken under a fluorescence
microscopy. GFP-LC3 puncta (mean ± SD) were quantified for each experiment. At least 20 cells were counted in each individual experiment.
(**: P < 0.01). (C) Electron micrographs showing the cells ultrastructure as indicated. Black arrows indicate the autophagic vacuoles in the
cytoplasm. (Bar: 20 μm). (D) The number of autophagosomes were quantified (mean ± SD) (*: P < 0.05) (E) Whole cell lysates were subjected to
western blot to detect the expression of LC3 and p62 as indicated (for 0, 6, 12 and 24 hours). (F) LC3 and the p62 as indicated (for 25, 50, 100,
200, 400 μM) were examined by immunoblotting.
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massive positive immuno-reactivity of 8-OHdG was found
in BDL-treated liver, and much stronger intensity was
observed after co-treatment with CQ. Tretreatment of
rapamycin showed weak expression, suggesting that au-
tophagy contributes to minimize the accumulation of
ROS (Figure 5A and B). To evaluate whether enhanced
ROS levels may contribute to the cell death of hepatocytes
induced by cholestasis, we applied the N-acety-L- cysteine
(NAC) to eliminate ROS. As shown in Figure 5C, pre-
incubation with ROS scavenger NAC significantly allevi-
ated cell death upon GCDC treatment. It can be found
that NAC prominently promoted the survival of L02 cells
in the CQ+GCDC group. Furthermore, liver injury after
NAC treatment determined by ALT and AST level isshown in Figure 5D. Not surprisingly, the ALT and AST
levels in serum were significantly reduced in CQ + BDL
group after inhibiting ROS by NAC. This finding indi-
cated that ROS is involved in the hepatocytes cytotoxic
induced by cholestasis. Therefore, we conclude that au-
tophagy protected hepatocytes from cholestatic injury
by decreasing ROS activity.
Discussion
The major finding of this study is that autophagy is a
survival mechanism for liver to protect against cholestasis-
induced hepatocyte injury. Our results showed that block-
ade of autophagy by autophagic inhibitor-CQ exacerbated
cholestasis-induced liver injury and hepatocytes death. In
contrast, inducer of autophagy by rapamycin could partly
Figure 3 Induction of autophagy protects against cholestatic injury in vivo. Wild-type C57BL/6 mice were pretreated with Rapamycin or
CQ intraperitoneally two or three times one week for two weeks, which was followed by BDL induction. Two weeks later, mice were sacrificed
and were divided into seven groups: Control, CQ, BDL, CQ + BDL, Rap, BDL + DMSO, Rap + BDL. (A) Blood ALT and AST levels were examined
and quantified in each group.(*: P < 0.05). (B) Apoptosis of different groups were determined by TUNEL assay and visualized by microscope.
(C) The number of apoptosis (mean ± SD) was quantified from each group. More than 30 cells were counted in each experiment. (*: P < 0.05).
(D) Representive photographs of H&E staining were presented. Original magnification: ×200.
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tion of ROS by autophagy could contribute to the cell sur-
vival during cholestasis.
Autophagy is an essential component occurs at low
basal level in most cells to perform homeostasis functions
such as protein and organelle tunerover, and be upregu-
lated when response to some stressors. Activation of
autophagy has been reported with liver injury induced bysteatosis, alcoholic consumption, ischemia/reperfusion
and toxic drugs [19,25-27]. For example, in liver ischemia
reperfusion injury, autophagy mainly has a prosurvival ac-
tivity, allowing the cell for coping with nutrient starvation
and anoxia [28,29]. However, using animal models to
study whether autophagy is involved in and its function
has not been reported in this particular condition induced
by cholestasis. We suspect that the enhancing autophagic
Figure 4 Induction of autophagy protects against GCDC-induced cell apoptosis. (A) L02 hepatocytes cells were transiently transfected with
GFP-LC3 before treated with GCDC (200 μM), and then administered in the absence or presence of CQ (10 μM) or Rapamycin (2 μM) for 24 hours.
(B) The percentage of cells with punctuate GFP-LC3 was measured; at least 30 cells were counted in each individual experiment. Data of at least
three replicates were shown as (means ± SD) (*: P < 0.05). (C) In the absence or presence of CQ (10 μM), immunoblots were used to analyze
endogenous LC3 expression, with β-actin as a loading control. (D and E) L02 hepatocytes were treated as indicated and the apoptosis was
analyzed by flow cytometry using Annexin V-FITC. Data were shown individually as the (means ± SD) (*: P < 0.05, **: P < 0.01).
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environment and serve as an effective survival strategy to
clearance of abnormal or damaged hepatic proteins and
organelles. In our study, we found that autophagy was ac-
tivated when liver cells explore to GCDC or BDL in vitro
or in vivo at first. Then the result from the serum and cell
morphology showed that treatment with CQ would exac-
erbated the hepatic injury by increasing apoptosis in cho-
lestasis. Conversely, administration of the rapamycin
significantly promoted the liver survival. Our data suggest
that autophagy help hepatocyte overcoming cholestatic in-
jury. Similarly, the protective effect of autophagy restores
sevoflurane preconditioning lost by longer ischemic [30]
and APAP induced hepatotoxicity [19]. These findingsindicate that autophagy activation in cholestatic injury dir-
ectly contributes to the survival of liver cells.
How autophagy promotes cell survival to cholestasis
environment, however, remains to be explored. Detec-
tion of apoptosis and necrosis are further conducted in
liver tissue and hepatocytes. Apoptosis has been ob-
served to occur with necrosis following BDL, but in vitro
only apoptosis is to present the major cell death treated
with GCDC. There may be two reasons for this
phenomenon. First, actual bile salt concentration con-
tacted in liver is not entirely consistently in vivo and in
vitro. Second, the liver injury induced by cholestasis in-
cludes many factors, such as oxidative stress, mitochon-
drial damage, and cell membrane disruption and so on.
Figure 5 Autophagy protects hepatocytes from cholestatic injury by eliminating ROS. (A) L02 normal liver cells were incubated with GCDC
for 24 h with 10 μM CQ. Cellular ROS activity was determined using DCF-DA staining. (B) Immunohistochemical staining of 8-OhdG in the liver
of mice. (C) L02 normal liver cells were pretreated with 10 mM NAC for 2 h, and cells were incubated in GCDC (200 μM) or with 10 μM CQ for
the indicated time. Cell viability was assessed by MTT assay. Data (mean ± SD) were determined in at least three independent experiments.
(*: P < 0.05). (D) Mice were treated as indicated and serum levels of ALT and AST were determined. Data were expressed as mean ± SD.
(**: P < 0.01).
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results in different stimulation effects on bile acids ef-
fects. Our findings showed that there was no difference
in necrosis but apotosis between the CQ and CQ +
GCDC group. All of these results supported our hypoth-
esis that pretreated with CQ exacerbated the hepatic
injury due to increased apoptosis in cholestasis. Con-
versely, rapamycin administration would have the oppos-
ite effect, restoring the cell death. Previous report has
been shown that autophagy, apoptosis and necrosis can
overlap and autophagy delays the onset of both apop-
totic and necrotic cell death in a model of ischemic cell
death [31].
ROS was shown to act as a critical signal in the patho-
genesis of bile acid-induced hepatocyte injury [23].
In our study, we also found that cholestasis-induced
autophagic activation, at least partially, via oxidative
stress, which is critical for liver cells survival. We haveobserved a modest increase in cellular ROS activity
caused by GCDC or BDL with model of cholestasis.
Combination of CQ and GCDC or BDL resulted in a
marked increase in ROS generation while surpression of
ROS generation was shown when pretreated with rapa-
mycin. More importantly, increased levels of ROS con-
tributed to cell death and liver damage in cholestatic
liver cells and tissues when autophagy was inhibited, but
treatment with the antioxidant NAC antioxidant mark-
edly reduced this phenonemon. Consisting with these re-
ports, Ding ZB et al. found oxaliplatin-induced ROS
generation is augmented by autophagy inhibition and
has an important role in cell death [32]. Sun K et al.
stated that induction of autophagy reducing ROS-induced
necrosis to suppressed ischemic liver injury [27]. Our
results support that autophagy is a cellular self-defense re-
sponse to alleviate cholestasis-induced liver injury through
modulating oxidative stress. However, current study has
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portant source of ROS [33]. Thus, it is conceivable that
autophagic degradation of damaged mitochondria is a part
of the protection mechanism against cholestatic liver in-
jury. Our work, however, does not clarify the specific
mechanisms via which autophagy modulates ROS, espe-
cially the role of mitophagy in the cholestasis induced he-
patocytes injury. Further studies are warranted in future.
In this study, we found that activation of autophagy
can enhance the survival of liver injury induced by cho-
lestasis. A proper autophagy capability in the liver may
be crucial to reduce the detrimental effects of cholesta-
sis, and that enhancement of autophagy may be a pos-
sible therapeutic strategy to mitigate the pathology
associated with cholestasis liver disease.
Methods
Animals model
Male C57BL/6 mice, 6–8 weeks old, weighting 20-25 g,
were purchased from the Shanghai Experimental Animal
Center of the Chinese Academy of Sciences, Shanghai,
China. All mice used in this study were housed in
pathogen-free conditions, and all procedures were per-
formed in accordance with guidelines established by the
Chinese Academy of Sciences’ Committee on Animals.
The animals received the laparotomy with bile duct
ligaltion were performed as previously described in de-
tail [34]. In the control group, mice had undergone the
surgical procedures but without BDL. Induction or sup-
pression of autophagy was achieved by intraperitoneal
administration of chloroquine (60 mg/kg), rapamycin
(2 mg/kg) unless otherwise indicated in figure legends.
Regents
Chloroquine (CQ), Rapamycin, Glycochenodeoxycholate
(GCDC) and N-acetyl-cysteine (NAC) were purchased
from Sigma-Aldrich (St Louis, MO).
Transient transfection and identification of autophagy
GFP-tagged LC3 expression vector has been utilized to
demonstrate the occurrence of autophagy and was de-
tected using an inverted fluorescence microscope. L02
cells were seeded (1 × 103cells/well) in 96-well plates
overnight and were transiently transfected with GFP-
LC3 expressing plasmids using Fugene HD transfection
reagent (Calbiochem, La Jolla, CA) according to the
manufacturer’s instructions. After initial treatment,
autophagy was detected by counting the number of GFP-
LC3-positive dots per cell under fluorescence microscope
(Olympus IX71).
Measurement of liver function
Two weeks after BDL, blood samples were collected from
all mice. The plasma alanine aminotransferase (ALT),aspartate aminotransferase (AST) and totalbilirubin (TBIL)
levels were tested with a biochemical autoanalyzer (Fuji
Medical System, Tokyo, Japan) according to the manufac-
turer’s instructions.
Western blot analysis
After special treatment, cells and tissues were lysed in
RIPA lysis buffer (Beyotime) with 1 mM PMSF. Equal
amount of protein was separated by SDS-PAGE and
transferred to NC membrane. The membranes were
washed, blocked, and incubated with specific primary
anti-human antibodies against LC3 (Novus Biologicals,
Littleton, CO) and p62/SQTM (Cell signaling Technol-
ogy, Beverly, MA), β-actin antibody (Hangzhou HuaAn
Biotech, Zhejiang, China), followed by incubation with
horseradish peroxidase-conjugated secondary antibodies
(Hangzhou HuaAn Biotech). Signals were visualized by
chemiluminescent detection (Beyotime).
Histological examination and tunnel staining
Liver tissues were fixed in 4% paraformaldehyde, sec-
tioned, and mounted on glass slides then stained with
Meyer’s hematoxylin and eosin. Each sample was observed
at a 200× magnification of microscopic field in 5 randomly
selected areas. Tunnel staining (Calbiochem, La Jolla, CA)
was used to assess the apoptosis level of paraffin-
embedded fraction slides, according to the manufacturer’s
instructions. The number of positive-apoptotic cells were
counted and expressed to the total number of cells within
5 random fields (200×) of cells.
Electron microscopic analysis
At room temperature cells were fixed in 2.5% glutaralde-
hyde in PBS (pH = 7.4) for two hours, postfixed in 1%
osmium tetroxide in water for one hour. After dehydrat-
ing in an ascending series of ethanol, the samples were
then embedded in araldite. 50-60 nm sections were cut
on a LKB-I ultramicrotome and picked up on copper
grids, post-stained with uranyl acetate and lead citrate,
observed in a Philips CM-120 TEM.
Flow cytometric analysis
Annexin V-fluorescein isothiocyannate (FITC) assay was
used to measure cell death by flow cytometry according to
the manufacturer’s instructions (Nanjing Keygen Biotech,
China). Briefly, cells were collected together and resus-
pended in 300 μl 1 × binding buffer containing 5 μl of
Annexin V and 5μof PI for 30 min at room temperature in
the dark. After incubation, samples were analyzed by a BD
FACSAria flow cytometer within one hour.
Measurement of intracellular ROS level
To examined the accumulation of reactive oxygen
species (ROS), cells were incubated with 10 μM 2’,
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for 30 min at 37°C, respectively, followed by fluores-
cence microscopy.
Statistical analysis
All of the experiments were repeated at least three times.
Quantitative data were expressed as mean ± SD. Signifi-
cance between two groups was performed with the Stu-
dent’s t test. P < 0.05 was considered statistically significant.
Statistical analysis was performed with GraphPad Prism
5.0 software.
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